Sensei biotherapeutics announces 1-for-20 reverse stock split

Boston, june 13, 2025 (globe newswire) -- sensei biotherapeutics, inc. (nasdaq: snse), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that it will implement a 1-for-20 reverse stock split of its issued and outstanding shares of common stock ("reverse stock split"), effective at 5:00 p.m. eastern time on june 16, 2025. the reverse stock split was approved by the company's stockholders at the company's annual meeting of stockholders held on may 21, 2025, with the final ratio subsequently determined by the company's board of directors. the reverse stock split is intended to bring the company into compliance with the minimum bid price requirement for continued listing on the nasdaq capital market.
SNSE Ratings Summary
SNSE Quant Ranking